Cardinal Health

Cardinal Health’s edge is scale and efficient‑scale economics in U.S. drug distribution. Three national players, massive fixed‑cost networks, DEA/FDA compliance, and decades‑long customer relationships make local entry uneconomic. Red Oak Sourcing with CVS adds a negotiated generics cost advantage.

We view moats by component: cost advantage 70/100 (scale, procurement via Red Oak); efficient scale 65/100 (national network with high fixed costs, thin returns deter entrants); switching costs 55/100 (large contracts can and do move, as OptumRx did, but transitions are complex and risky); intangible assets 50/100 (brand and compliance know‑how matter but are not exclusive); network effects 35/100 (some data and contracting benefits in Specialty/MSOs and Nuclear, but not classic two‑sided network power).

Risks to moat: vertical integration by payers/pharmacies, regulatory changes, sustained generic deflation, and execution missteps in Medical. Mix shift to specialty and services could strengthen qualitative moats over time if platforms scale.